Research
Metabolic adaptation
GLP-1 receptor agonists reduce central adiposity, SBP, DBP, and insulin resistance.
Practitioners should consider GLP-1 receptor agonists for improving metabolic health in this population.
StrongSupportsmedium confidence
These therapies reduce central adiposity, SBP and DBP and insulin resistance.
Why this rating
Based on the mention of clinical trial data.
Source
A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Ayesha Malik et al. · Journal of Hypertension · 2026
cohort
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →